Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Total Valuation
Cardiol Therapeutics has a market cap or net worth of C$215.91M. The enterprise value is C$178.62M.
Market CapC$215.91M
Enterprise ValueC$178.62M
Share Statistics
Cardiol Therapeutics has 111,872,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding111,872,086
Owned by Insiders2.32%
Owned by Institutions6.31%
Financial Efficiency
Cardiol Therapeutics’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -190.61%.
Return on Equity (ROE)-1.89
Return on Assets (ROA)-1.43
Return on Invested Capital (ROIC)-190.61%
Return on Capital Employed (ROCE)-1.91
Revenue Per Employee0.00
Profits Per Employee-1.88M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiol Therapeutics is ―. Cardiol Therapeutics’s PEG ratio is 0.14.
PE Ratio―
PS Ratio0.00
PB Ratio6.37
Price to Fair Value6.37
Price to FCF-4.77
Price to Operating Cash Flow-8.11
PEG Ratio0.14
Income Statement
In the last 12 months, Cardiol Therapeutics had revenue of 0.00 and earned -33.82M in profits. Earnings per share was -0.39.
Revenue0.00
Gross Profit0.00
Operating Income-34.32M
Pretax Income-33.82M
Net Income-33.82M
EBITDA-34.21M
Earnings Per Share (EPS)-0.39
Cash Flow
In the last 12 months, operating cash flow was -23.85M and capital expenditures -24.48K, giving a free cash flow of -23.88M billion.
Operating Cash Flow-23.85M
Free Cash Flow-23.88M
Free Cash Flow per Share-0.21
Dividends & Yields
Cardiol Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.27
52-Week Price Change37.69%
50-Day Moving Average1.47
200-Day Moving Average1.54
Relative Strength Index (RSI)61.25
Average Volume (3m)136.50K
Important Dates
Cardiol Therapeutics upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Cardiol Therapeutics as a current ratio of 4.16, with Debt / Equity ratio of 0.70%
Current Ratio4.16
Quick Ratio4.16
Debt to Market Cap0.00
Net Debt to EBITDA0.62
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiol Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cardiol Therapeutics EV to EBITDA ratio is -2.71, with an EV/FCF ratio of -3.88.
EV to Sales0.00
EV to EBITDA-2.71
EV to Free Cash Flow-3.88
EV to Operating Cash Flow-3.88
Balance Sheet
Cardiol Therapeutics has C$21.42M in cash and marketable securities with C$125.52K in debt, giving a net cash position of C$21.29M billion.
Cash & Marketable SecuritiesC$21.42M
Total DebtC$125.52K
Net CashC$21.29M
Net Cash Per ShareC$0.19
Tangible Book Value Per ShareC$0.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cardiol Therapeutics is C$11.81, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$11.81
Price Target Upside511.88% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast21.17%